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ABSTRACT 
 
Background: There is high prevalence of Cytomegalovirus (CMV) in pregnancy worldwide, 
primary infection in particular has been associated with significant haematological changes and 
childhood neurodevelopmental disabilities. There is however, paucity of information on the effect of 
CMV seropositivity in pregnancy on the haematological parameters of pregnant women from our 
centre. 
Aim: This study was therefore designed to determine the effects of CMV sero-positivity among 
pregnant women, in Makurdi Nigeria, on some key haematological parameters. 
Methods: A cross sectional study of 211 pregnant women aged 15-50 years attending antenatal 
clinic at The Benue State University Teaching Hospital & Federal Medical Centre, Makurdi, Nigeria, 
from November 2016 to April 2017 was conducted. They were screened & grouped based on their 
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CMV status into three groups: The overall CMV status (irrespective of antibody type), CMV IgG 
status and CMV IgM status. Their Mean White Blood Count (WBC), Platelet Count, Absolute 
Neutrophil Count (ANC), Absolute Lymphocyte Count (ALC) and Haemoglobin (Hb) levels were 
estimated & compared. Data obtained were coded, entered and analysed with SPSS version 20. 
Simple proportion was used to determine CMV positivity. The independent sample t-test and 
Pearson's chi-square were used for comparison of quantitative variables and chi-square test for 
qualitative variables. Relationships were determined, and a P< .05 was considered significant. 
Results: The younger pregnant women age 21-30 years constituted 75.4%, and represented the 
highest respondents. In those who were CMV IgG positive, WBC, platelets, ALC & haemoglobin all 
appeared lower & ANC appeared higher. In the CMV IgM positive, Haemoglobin & platelets 
appeared lower, while WBC, ANC & ALC all appeared higher. Overall, in those positive for CMV 
(irrespective of antibody type), WBC, platelet and haemoglobin appeared lower and ANC & ALC 
appearing higher. In all, these differences were not statistically significant, with P> .05 
Conclusion: Cytomegalovirus seropositivity was found not to have any statistically significant 
effect on the haematological parameters of the pregnant women. We recommend further research 
in this area, education, and follow up on women with primary infection.  
 
 
Keywords: Cytomegalovirus; immunoglobulin; pregnant women. 
 
1. INTRODUCTION 
 
Human Cytomegalovirus (HCMV) is a human 
herpesvirus type 5 (HHV-5), & belongs to the 
herpesviridae family [1]. 
  
New (primary) Cytomegalovirus (CMV) infection 
is common during childhood, consequently 
seroprevalence in the general human population 
is very high [2,3]. The prevalence of CMV 
infection ranges between 30%-90%, and the rate 
of infection increases with age [2]. One study in 
the United States documented a steady increase 
in CMV prevalence from 36.3% to 90.8% in 6–
11-year-olds to 80 years old age groups 
respectively [3]. Important risk factors for CMV 
infection include age, geographic location and 
socioeconomic factors, other risk factors include 
blood transfusion, kissing, breastfeeding, sexual 
contact, solid organ and haemopoietic stem cell 
transplantation [2].  
 
CMV is a highly pathogenic herpesviruses, 
Primary infection with the virus carries the 
highest chance of congenital infection & is 
associated with very high perinatal morbidity              
and mortality [2,4]. Congenital CMV infection is 
an important cause of neurodevelopmental 
abnormalities and the leading infectious cause of 
deafness in children [5,6].  
 
CMV has also been associated with significant 
haematological changes referred to as CMV 
mononucleosis syndromes and cytomegalic 
inclusion diseases [7,8]. Some of these         
changes include reactive lymphocytosis, 
monocytosis and variable cytopaenias, especially 
thrombocytopaenia. Disseminated Intravascular 
Coagulation (DIC) has also been a feature of 
CMV Vireamias [7,8]. 
 
Following primary CMV infection in an 
immunocompetent person, the virus persists for 
years in a latent phase and may not lead to any 
clinically important illness, while in immune 
compromised individuals such as pregnant 
women, foetuses, HIV-infected hosts, organ 
transplant recipients and patients on 
immunosuppressive drugs, reactivation may 
occur years later [9,10]. 
.  
In the immunocompromised persons, both 
primary and reactivated (secondary) infections 
are associated with serious disease and 
complications. In pregnant women, the highest 
risk is with foetus and the new-borns [5,6]. The 
risk of symptomatic congenital infection is lower 
in a reactivated (secondary) than in primary CMV 
infection, this is because the maternal CMV 
antibodies present in the case of reactivated 
infection tend to prevent intrauterine transmission 
[6].  
 
On CMV latency & reactivation, monocytes and 
macrophages have been implicated, suggesting 
that macrophages and their lineage cells provide 
a long-lived site for CMV latency [11,12]. The 
viral genome is carried and remained in the 
primitive hematopoietic mononuclear cells of the 
peripheral blood and bone marrow during latency 
and that reactivation occurs as the macrophage 
or dendritic lineage cells differentiate [11,12]. 
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Maternal CMV infections are usually 
asymptomatic, and so diagnosis of maternal 
CMV infection is mostly via laboratory means, 
the diagnosis can either be by tissue culture viral 
isolation or by serologic technique [13]. The viral 
antigen in tissue culture (used to confirm 
diagnosis) can be identified & isolated within 
twenty hours by viral shell assay, immune-
fluorescent staining, monoclonal antibody, and 
PCR techniques [13,14]. Evidence of maternal 
IgM seroconversion (i.e. in a previously negative 
person), is needed to confirm the diagnosis of a 
primary infection, however the use of maternal 
CMV IgM in the diagnosis of primary infection 
has some limitations; IgM antibodies can persist 
after primary infection for months to even years, 
it can also be seen in reinfection or in 
reactivation [13,15].  
 
IgG antibody avidity can be used to differentiate 
acute recent from past infection, and this is 
based on the fact that avidity increases as 
immune response to a particular antigen matures 
over time, and that means that the more recent 
the infection, the less the avidity, while the less 
recent the infection the stronger the avidity [15]. 
Thus low avidity anti-CMV IgG early in 
pregnancy suggests a recent acute infection, and 
this can be used to know pregnant women at 
higher risk of foetal infection and complication, 
while high-avidity IgG antibodies up to 16 weeks 
of gestation signifies past infection, most likely 
before conception [15].  
 
While routine CMV infection screening in 
pregnancy has not yet been recommended by 
CDC, educating pregnant women and women 
planning to get pregnant, about CMV prevention, 
has been recommended [16,17]. It was stated 
that this knowledge will help them to know how 
careful and cautious they must be to avoid 
getting infected [16,17]. Failure to recommend 
routine CMV screening was because of the 
difficulties of establishing diagnosis and the lack 
of effective therapy against CMV in pregnancy 
[16,17].   
 
While some countries still view cytomegalovirus 
as a benign opportunistic pathogen that is not 
likely to produce any significant clinical infection, 
others like UK have already made attempts at 
two routine CMV screening [16,17]. In the UK, 
the first screening was antenatal, to detect 
women who acquire the infection in pregnancy 
and second was neonatal screening of the infant 
to detect infants with congenital infection who are 
at risk of adverse sequel, although this approach 
is still subject to periodic review [16,17].  
At the time of this work, extensive literature 
search yielded no published work on the 
assessment of haematological parameters 
among CMV antibody positive pregnant women 
from our centre. This glaring information dearth 
necessitated this study. Again, Leukocytosis, 
physiological anaemia and gestational 
thrombocytopaenia from haemodilution are 
known common haematologic effects of many 
normal pregnancies [18], it would therefore be 
interesting to know whether or not, CMV infection 
& pregnancy exert combined effect on the 
haematological parameters. This study design 
therefore aimed to evaluate the effect CMV 
seropositivity on some major haematological 
indices among pregnant women seeking 
antenatal care at tertiary health care centres in 
Makurdi. 
 
2. MATERIALS AND METHODS 
 
This was a cross sectional study of pregnant 
women aged 15-50 years, attending antenatal 
clinic at The Benue State University Teaching 
Hospital & Federal Medical Centre, Makurdi, 
Nigeria, from November 2016 to April 2017. Two 
hundred and eleven (211) of them were selected 
through random sampling and grouped based on 
their CMV status into overall CMV status 
(irrespective of antibody type), CMV IgG status 
and CMV IgM status. Ethical approval was 
obtained from the research and ethical 
committee of Federal Medical Centre, Makurdi. 
Informed consent was obtained from all the 
participants. Relevant personal, social and 
demographic information were obtained with             
the aid of a pretested self-administered 
questionnaire. Non-consenting pregnant women 
were excluded from the study.  
 
Six millilitres (6 ml) of venous blood was 
collected aseptically from each of the consenting 
pregnant women. Three (3) ml was dispensed 
into an ethylene diamine tetra acetic acid (EDTA) 
anticoagulant bottle which was analysed within 5 
hours of collection, using an automated 
haematology analyser by Sysmex XN series. 
White cell count (WBC), Platelets count, 
Absolute Neutrophil Count (ANC), Absolute 
Lymphocyte Count (ALC) & haemoglobin (Hb) 
concentration were estimated. These tests were 
done according to manufacturer’s instructions 
and the results were interpreted and documented 
accordingly. The remaining 3ml of whole blood 
was emptied into a sterile labelled plain 
vacutainer tube and was allowed to clot by 
standing at room temperature and then spun in a 
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centrifuge at 2500 g for 5 minutes to separate the 
serum. The sera were then dispensed into a 
cryovials and stored at –20°C until required                
for use. The sera were screened for CMV-IgG 
and CMV-IgM antibodies with Enzyme-Linked 
Immunosorbent Assay (ELISA) by Sekisui 
Verotech GmbH Löwenplatz 5 65428 
Rüsselsheim Germany. 
 
2.1 Virotech ELISA Test Procedures  
 
Purified CMV antigen micro-wells were used. For 
each test run, 100µl each of dilution buffers 
(blank), IgG and IgM-positive, negative and cut-
off controls (calibrator control) as well as diluted 
patient sera were pipetted.  
 
Hundred (100)µl of these and Patient serum 
were added to the wells in duplicates,  incubated 
for 30 min. at 37°C (with cover). All unbound 
materials were washed 4 times. Conjugate 
reagent was added into the washed test solution 
and then Incubated for 30 min. at 37°C (with 
cover). Excess conjugate was washed off and a 
solution of 3,3',5,5'-Tetramethylbenzidine (TMB) 
reagent was added and incubated for 30 min. at 
37°C (with cover). Then 50µl of citrate stopping 
solution was added into each well.  The plate 
was agitated carefully and thoroughly until liquid 
was completely mixed and a homogeneous 
yellow colour was visible. 
 
Extinction (OD) was measured at 450/620 nm 
(Reference Wavelength 620-690 nm). The 
photometer was set such that the blank value 
was deducted from all other extinctions. 
Extinctions were measured within 1 hour after 
adding the stopping solution.  
 
The intensity of the colour generated was 
propositional to the amount of IgG or IgM specific 
antibody in the sample. The results were read by 
a micro-well reader compared in a parallel 
manner with cut-off control (calibrator) and 
controls. 
  
2.1.1 Test function control  
  
a.  OD-values  
 
The conditions were that OD of the blank 
should be < 0.15. The OD-values of the 
negative controls were to be lower than the 
OD-values mentioned in the Quality Control 
Certificate. The OD-values of the positive 
controls as well as of the cut-off controls were 
to be above the OD-values mentioned in the 
Quality Control Certificate.  
b.  Virotech units (VE)  
 
The Virotech Units (VE) of the cut-off controls 
were defined as 10 VE. The calculated VE of 
the positive controls were to be within the 
ranges mentioned in the Quality Control 
Certificate. 
 
Where these requirements (OD-values, VE) 
were not fulfilled, the test was to be repeated.   
 
2.1.1.1 Calculation of the Virotech Units (VE)  
 
The extinction of the blank value (450/620 nm) 
was subtracted from all other extinctions. 
 
VE (positive control) =OD (positive control)/ 
OD (cut-off control) x 10 
 
VE (patient serum) = OD (patient serum)/OD 
(cut-off control) x 10 
 
Interpretation Scheme IgG and IgM Result 
 
Result (VE)  Evaluation 
 
<9.0  Negative 
9.0-11.0  Borderline 
>11.0  Positive 
 
1. When the measured values were above 
the defined borderline range, they were 
considered to be positive.  
2. When the measured VE was within the 
borderline range, no significant high 
antibody concentration was present, the 
samples were considered to be borderline  
3. When the measured values were below 
the defined borderline range, no 
measurable antigen specific antibodies 
were present in the samples. The samples 
were considered to be negative. 
 
2.2 Data Analysis 
 
Data obtained were coded, entered and analysed 
with SPSS (Statistical Package for the Social 
Sciences) version 20. The Means & standard 
deviation (SD), using ANOVA, were calculated 
for the haematological parameters. Simple 
proportion was used to determine CMV positivity. 
The independent sample t-test and Pearson's 
chi-square were used for comparison of 
quantitative variables and chi-square test for 
qualitative variables. Relationships were 
determined, and a P< .05 was considered 
significant. 
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3. RESULTS 
 
3.1 Age and CMV Status of Respondents 
 
Most of the 211 respondents attending antenatal 
clinics in our centre were young pregnant 
women, 159(75.4%), between 21-30 years of 
age, and the occurrence of CMV IgM, 1(12.5%) 
& 9(5.7%), seemed higher in the younger 
respondents, while CMV IgG, 8(100%) & 
34(94.4%), seemed higher in the older women 
from 31-50 years of age (Table 1). The 
prevalence of CMV IgG was 94.3% and that of 
CMV IgM was 5.7% (Table 1). 
 
3.2 Haematological Parameters & CMV 
IgG Status  
 
WBC, platelets, ALC & haemoglobin all appeared 
lower & ANC appeared higher, these differences 
were however not statistically significant with                
P> .05. (Table 2). 
 
3.3 Haematological Parameters & CMV 
IgM Status 
 
Haemoglobin & platelets appeared lower in CMV 
IgM positive pregnant women, & WBC, ANC & 
ALC all appeared higher, the differences were 
also not significant, with P> .05 (Table 3). 
 
3.4 Haematological Parameters & Overall 
CMV Infection Status  
 
This is irrespective of CMV antibody type. WBC, 
platelet and haemoglobin appeared lower and 
ANC & ALC appeared higher among the 
pregnant women who were CMV positive, the 
difference was also not statistically significant 
with P> .05 (Table 4). 
 
Table 1. Age and CMV status of respondents 
 
  Ig M Ig G Total (%) 
n(%) n(%) 
Age (yrs) 15-20 1(12.5)  7 (87.5) 8(3.8) 
 21-30 9(5.7) 150(94.3) 159(75.4) 
 31-40 2(5.6) 34(94.4) 36(17.1) 
 41-50 0(0.0) 8(100) 8(3.8) 
Total  12(5.7) 199(94.3) 211(100) 
 
Table 2. Haematological parameters & CMV IgG status 
 
CMV IgG n(%) Haematological parameters 
WBC(x109/L) Plat(x109/L) ANC(x109/L) ALC(x109/L) Hb(g/dl) 
Pos 196(92.89) 6.71±1.27 221.49±56.61 9.21±3.17 2.13±0.60 11.03±0.69 
Neg 15(7.11) 6.81±1.62 234.07±72.33 8.57±3.22 2.13±0.66 11.46±0.84 
Total 211(100) 6.71±1.29 222.38±57.75 9.16 ±3.17 2.13± 0.60 11.06±0.71 
 
P -value .127 .494 .900 .690 .194 
 
Table 3. Haematological parameters & CMV IgM status 
 
CMV IgM n(%) Haematological parameters 
WBC(x10
9
/L) Platelets(x10
9 
/L) ANC(x10
9 
/L) ALC(x10
9 
/L) Hb(g/dl) 
Pos 8(3.79) 6.75±1.07 188.63±60.24 9.91±2.11 2.35±0.31 10.87±0.75 
Neg 203(96.21) 6.71±1.30 223.71±57.40 9.13±3.21 2.12±0.61 11.07±0.70 
Total 211(100) 6.71±1.29 222.38±57.75 9.16 ±3.17 2.13± 0.60 11.06±0.71 
 
P -value .848 .091 .491 .563 .309 
 
Table 4. Haematological parameters & overall CMV infection status 
 
CMV 
status 
n(%) Haematological parameters 
WBC(x10
9
/L) Platelets(x10
9 
/L) ANC(x10
9 
/L) ALC(x10
9 
/L) Hb(g/dl) 
Yes 197(93.36) 6.70±1.26 220.32±56.68 9.26±3.14 2.13±0.60 11.03±0.69 
No 14(6.64) 6.85±1.69 251.36±66.91 7.86±3.47 2.11±0.63 11.52±0.83 
Total 211(100) 6.71±1.29 222.38±57.75 9.16 ±3.17 2.13± 0.60 11.06±0.71 
 P -value .109 .095 .409 .764 .129 
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4. DISCUSSION 
 
In a study on CMV prevalence, the highest 
number of respondents, attending antenatal 
clinics in their centre was that of younger 
pregnant women [2,19]. This is similar to our 
finding and can be explained by the fact that the 
studies were done in the same geographic region 
with similar socio-cultural practices and religious 
believe. These factors support and promote early 
marriages and putting younger girls in the family 
way very early in life. 
 
Some studies from the region, reported higher 
occurrence of CMV IgM in their younger 
pregnant women and CMV IgG in the older 
pregnant women [2]. This again, is in agreement 
with our finding. This showed that more of the 
younger pregnant women had primary CMV 
infections, probably because they were exposed 
for the first time, had recent infection. Many may 
have had their first one or two pregnancies and 
getting exposed to smaller children and other risk 
factors for CMV infection. This also showed that 
the older pregnant women have been exposed 
much earlier and had old infections. There were 
few other studies that reported lack of 
association between age and CMV antibody 
types [20]. 
 
This finding has some implications, for example, 
the younger ones with recent or reactivated 
infections are more at risk of developing  
perinatal complications of CMV infection, either 
haematological or foetal. This also justified the 
need for this study, and calls for follow up and 
close monitoring of these women for onset            
and early detection of any haematological 
complication. In the older women, because of the 
existing predominant IgG antibodies, they are 
better protected from the perinatal and other 
haematological complications than the younger 
pregnant women with CMV IgM.   
  
The high prevalence of 94.3% for CMV IgG in 
our study is also worrisome, and this is the case 
with many of the studies from the region [19,21]. 
 
A study from Netherland reported CMV infection 
as a significant cause of delay platelet recovery 
after Bone Marrow Transplantation (BMT) [22]. 
The CMV positive group of patients had a 
significantly slower platelet & granulocyte 
recovery compared to the CMV negative group. 
This demonstrated a significant negative effect of 
cytomegalovirus infection on platelet and 
granulocytes. This study finding was however at 
variance with our findings. This may be explained 
by the difference in the study population groups, 
they used patients with already primary bone 
marrow diseases while we used apparently 
healthy pregnant women. Even though both 
conditions have the potentials to induce 
thrombocytopaenia, gestational & CMV induced 
thrombocytopaenia are more likely to be less 
significant. 
 
Similarly, in one case report, cytomegalovirus 
infection was reported to have caused 
cytomegalovirus induced severe 
thrombocytopaenia in a male patient [23]. Again 
this finding was in variance with ours, and may 
still be explained by the variation in study 
subjects.  
 
In another study, it was stated that some 
haematological parameters “suggestive of CMV 
infection include a differential white blood cell 
(WBC) count showing atypical lymphocytes and 
a low platelet count” [13].  
 
Overall, most of the studies reviewed 
documented low platelet in CMV positive 
pregnant women and variable effects of CMV on 
granulocytes and lymphocytes. Even though our 
study showed a similar pattern, with the overall 
effect of CMV infection (irrespective of antibody 
type), as lower platelet, haemoglobin & total 
WBC and higher neutrophil and lymphocytes, the 
findings were however not statistically significant.  
 
5. CONCLUSION 
 
Though, our study showed an apparent negative 
effect of CMV on the haematological parameters, 
this however was of no statistical significance. 
 
We recommend further research in this subject 
area, institution of routine education of pregnant 
women and women preparing to get pregnant, on 
CMV infection prevention, counselling them on 
the importance of careful hand hygiene practices, 
especially those exposed to young children, in 
order to decrease the risk of primary CMV 
infection with the attendant complications.  
 
There is also a need for follow up on pregnant 
women with high CMV IgM antibodies or 
evidence of recent or primary infection, for early 
detection of any haematologic complication. 
 
6. LIMITATION OF THIS STUDY 
  
During the study period, intense literature search 
yielded extremely low previous work on this 
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topic, and so there was paucity of information on 
the effect of cytomegalovirus seropositivity on the 
haematological parameters of pregnant women. 
Most of the cases found were on other study 
subjects, mostly men and non-pregnant women.  
 
The second limitation was our inability to carry 
out CMV IgG avidity test that would have been a 
better indication or otherwise of recent or primary 
infection.  
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